Tizanidine Tablet
NDC Package 68788-8741-2
Package Information
Tizanidine tablets is tizanidine is indicated for the management of spasticity. This formulation utilizes a tablet delivery system. Marketed by Preferred Pharmaceuticals Inc., this product is identified by NDC 68788-8741 and is authorized under FDA application ANDA076533.
Identification & Billing
- RxCUI: 313413 - tiZANidine HCl 4 MG Oral Tablet
- RxCUI: 313413 - tizanidine 4 MG Oral Tablet
- RxCUI: 313413 - tizanidine 4 MG (as tizanidine HCl 4.576 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68788 - Preferred Pharmaceuticals Inc.
- 68788-8741 - Tizanidine
- 68788-8741-2 - 20 TABLET in 1 BOTTLE
- 68788-8741 - Tizanidine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68788-8741). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68788-8741-2 identifies a specific commercial package of 20 tablet in 1 bottle of Tizanidine, a human prescription drug labeled by Preferred Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 20 billable units per package. This tablet is formulated for oral use and contains tizanidine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Preferred Pharmaceuticals Inc. on September 20, 2024. The current certification is valid through December 31, 2026.
How is this Preferred Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68788874102. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 20 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.